AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
AZ’s lung cancer drug Tagrisso gets boost from first line OS resultsAstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung Share XAZ’s lung cancer drug Tagrisso gets boost from first line OS resultshttps://pharmaphorum.com/news/azs-key-cancer-drug-tagrisso-gets-further-boost-from-os-results/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Sillajen explains Pexa-Vec trial failure – it was the rescue medsSouth Korean biotech Sillajen was hit hard last week when its oncolytic virus therapy Pexa-Vec failed a phase Share XSillajen explains Pexa-Vec trial failure – it was the rescue medshttps://pharmaphorum.com/news/sillajen-explains-pexa-vec-trial-failure-it-was-the-rescue-meds/
Roche scores with Tecentriq combo in first-line bladder cancerRoche’s Tecentriq has become the first checkpoint inhibitor to show a benefit in previously-untreated patients with bladder cancer Share XRoche scores with Tecentriq combo in first-line bladder cancerhttps://pharmaphorum.com/news/roche-scores-with-tecentriq-combo-in-first-line-bladder-cancer/
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourDaiichi Sankyo’s pexidartinib has become the first FDA-approved therapy for tenosynovial giant cell tumour (TGCT), a rare form Share XDaiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumourhttps://pharmaphorum.com/news/daiichi-sankyos-pexidartinib-is-first-fda-approved-drug-for-rare-tumour/
Exicure lists on Nasdaq, raising $55m for cancer, neurology pushUS biotech Exicure has raised $55 million in a public offering that has seen its shares elevated from Share XExicure lists on Nasdaq, raising $55m for cancer, neurology pushhttps://pharmaphorum.com/news/exicure-lists-on-nasdaq-raising-55m-for-cancer-neurology-push/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
NICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyNICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages Share XNICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyhttps://pharmaphorum.com/news/nice-backs-funding-for-azs-lynparza-ovarian-cancer-maintenance-therapy/
BMS shares fall on mixed cancer immunotherapy resultsBristol-Myers Squibb’s shares have fallen sharply in pre-opening trading after mixed results from its cancer immunotherapy Opdivo in Share XBMS shares fall on mixed cancer immunotherapy resultshttps://pharmaphorum.com/news/bms-shares-fall-on-mixed-cancer-immunotherapy-results/
AZ says recovery to continue to despite patent expiry and Brexit headwindsAstraZeneca has upped its revenue expectations following a strong second quarter, saying that sales of newer drugs will Share XAZ says recovery to continue to despite patent expiry and Brexit headwindshttps://pharmaphorum.com/news/az-says-recovery-to-continue-to-despite-patent-expiry-and-brexit-headwinds/
More woe for Roche as another Rituxan biosimilar approved in USThe FDA has approved a second biosimilar of Roche’s leukaemia drug Rituxan, along with yet another biosimilar of Share XMore woe for Roche as another Rituxan biosimilar approved in UShttps://pharmaphorum.com/news/more-woe-for-roche-as-another-rituxan-biosimilar-approved-in-us/
